fenofibric acid

DRUG3 trials

Sponsors

Mutual Pharmaceutical Company, Inc., Medical University of Vienna, HK inno.N Corporation

Conditions

ATRT RecurrentEpendymoma RecurrentHealthyMedulloblastoma RecurrentRare CNS Tumor Recurrent

Phase 1

Drug-Drug Interaction Study Between Fenofibric Acid and Efavirenz

CompletedNCT00960570

Mutual Pharmaceutical Company, Inc.Healthy

Start: 2008-02-29End: 2008-03-31Updated: 2012-08-07

To Compare Safety and Pharmacokinetic Properties of CJ-30039 and Lipidil Supra

CompletedNCT01501435

HK inno.N CorporationHealthy

Start: 2011-12-31End: 2012-06-30Updated: 2017-01-02

Phase 2

Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors

RecruitingNCT01356290

Medical University of ViennaATRT Recurrent, Ependymoma Recurrent, Medulloblastoma Recurrent +1

Start: 2014-04-01End: 2030-04-01Target: 232Updated: 2026-09-10

Related Papers

Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen

JAMA Oncology2023-10-2636 citations

Improved Long-Term Survival of Patients with Recurrent Medulloblastoma Treated with a “MEMMAT-like” Metronomic Antiangiogenic Approach

Cancers2022-10-1940 citations

Toward Improved Diagnosis Accuracy and Treatment of Children, Adolescents, and Young Adults With Ependymoma: The International SIOP Ependymoma II Protocol

Frontiers in Neurology2022-06-0231 citations

MBCL-43. RECURRENT MEDULLOBLASTOMA – LONG-TERM SURVIVAL WITH A “MEMMAT” BASED ANTIANGIOGENIC APPROACH

Neuro-Oncology2020-12-016 citations

INNV-36. A METRONOMIC ANTIANGIOGENIC COMBINATION THERAPY MAY PROLONG SURVIVAL FOR PATIENTS WITH RECURRENT MEDULLOBLASTOMA AND ATYPICAL TERATOID RHABDOID TUMOR

Neuro-Oncology2018-11-01

P05.32 Update on a metronomic antiangiogenic combination therapy for recurrent atypical teratoid rhabdoid tumor

Neuro-Oncology2018-09-01

MBCL-27. RESPONSE OF RECURRENT MALIGNANT CHILDHOOD CNS TUMORS TO A MEMMAT BASED METRONOMIC ANTIANGIOGENIC COMBINATION THERAPY VARIES DEPENDENT ON TUMOR TYPE: EXPERIENCE IN 71 PATIENTS

Neuro-Oncology2018-06-014 citations

OS02.5 Prolonged survival of patients with recurrent medulloblastoma and atypical teratoid rhabdoid tumor treated with an antiangiogenic metronomic combination therapy

Neuro-Oncology2017-04-01

ANGI-14UPDATE ON A METRONOMIC ANTIANGIOGENIC COMBINATION THERAPY FOR RECURRENT MEDULLOBLASTOMA AND ATYPICAL TERATOID RHABDOID TUMOR

Neuro-Oncology2015-11-01